All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Catherine ThieblemontScientific Advisory Board Member
Professor Catherine Thieblemont is the Head of the Hemato-Oncology Department at Hôpital Saint-Louis, Paris, FR. Her expertise lies in chronic lymphoproliferative syndromes, such as Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia. As the Head of the Hemato-Oncology Department, she contributes to clinical research, including the evaluation of clinical activity in phase II and III trials, as well collaborating with the Center for Clinical Investigations to oversee phase I trials.
Prof. Thieblemont is also a key collaborator with the Université Paris Descartes as part of the NFKB, Differentiation and Cancer group (EA7324), and sits on the Scientific Committee of the European School of Haematology.